We first started buying ACAD in the $6.00 range here ACAD - Pharmaceutical in February. Today the stock was up 12.64% to $16.58 on heavy volume. There wasn't a public press release from the company today to prompt the move higher, so I expect it was general funds buying the story of long term potential. Below is a daily chart of ACAD.
Bottom Line: We have no intention of selling the shares anywhere near these prices, as the future opportunity looks strong for their lead drug Pimavanserin for both Parkinson's and Alzheimer's disease. Thank you for reading.
